Forte Biosciences Inc.

NASDAQ: FBRX · Real-Time Price · USD
10.34
-0.01 (-0.10%)
At close: Jun 06, 2025, 10:06 AM

Company Description

Forte Biosciences, Inc. operates as a clinical-stage biopharmaceutical company in the United States.

It is developing FB-102 program that addresses various autoimmune diseases, such as vitiligo and alopecia areata.

The company is headquartered in Dallas, Texas.

Forte Biosciences Inc.
Forte Biosciences Inc. logo
Country United States
IPO Date Apr 13, 2017
Industry Biotechnology
Sector Healthcare
Employees 14
CEO Dr. Paul A. Wagner Ph.D.

Contact Details

Address:
3060 Pegasus Park Drive
Dallas, Texas
United States
Website https://www.fortebiorx.com

Stock Details

Ticker Symbol FBRX
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency USD
CIK Code 0001419041
CUSIP Number 34962G109
ISIN Number US34962G1094
Employer ID 26-1243872
SIC Code 2834

Key Executives

Name Position
Dr. Paul A. Wagner Ph.D. Chief Executive Officer, President & Chairman
Antony A. Riley CPA Chief Financial Officer
Christopher Roenfeldt Chief Operating Officer
Dr. Barbara K. Finck M.D. Chief Medical Clinician & Director

Latest SEC Filings

Date Type Title
May 30, 2025 8-K Current Report
May 15, 2025 SCHEDULE 13G/A [Amend] Filing
May 15, 2025 10-Q Quarterly Report
May 15, 2025 8-K Current Report
May 14, 2025 SCHEDULE 13G/A [Amend] Filing
Apr 30, 2025 ARS Filing
Apr 30, 2025 DEF 14A Filing
Apr 18, 2025 8-K Current Report
Apr 04, 2025 8-K Current Report
Apr 02, 2025 4 Filing